These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25280537)

  • 1. Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
    Meyer zu Schwabedissen HE; Siegmund W; Kroemer HK; Rollnik JD
    BMC Res Notes; 2014 Oct; 7():688. PubMed ID: 25280537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.
    Mukai Y; Narita M; Akiyama E; Ohashi K; Horiuchi Y; Kato Y; Toda T; Rane A; Inotsume N
    Biol Pharm Bull; 2017; 40(7):1078-1085. PubMed ID: 28674251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Woman Experienced Severe Thrombocytopenia When Treated With Fluvastatin].
    Potier A; Dony A; Crapsky A; Ferry O; Piney D; Dufay E
    Therapie; 2015; 70(6):541-4. PubMed ID: 26238127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
    Baek SD; Jang SJ; Park SE; Ok TJ; Leem J; Lee HS; Park SJ; Kim TH
    J Korean Med Sci; 2011 Dec; 26(12):1634-7. PubMed ID: 22148003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study.
    Miroševic Skvrce N; Božina N; Zibar L; Barišic I; Pejnovic L; Macolic Šarinic V
    Pharmacogenomics; 2013 Sep; 14(12):1419-31. PubMed ID: 24024895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
    Sinzinger H; Schmid P; O'Grady J
    Atherosclerosis; 1999 Apr; 143(2):459-60. PubMed ID: 10217378
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluvastatin, rhabdomyolysis, and myotoxicity.
    Murinson BB; Maragakis NJ; Jacobson TA
    Mayo Clin Proc; 2008 Nov; 83(11):1296; author reply 1297. PubMed ID: 18990330
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
    Ruggenenti P; Perna A; Tonelli M; Loriga G; Motterlini N; Rubis N; Ledda F; Rota S; Satta A; Granata A; Battaglia G; Cambareri F; David S; Gaspari F; Stucchi N; Carminati S; Ene-Iordache B; Cravedi P; Remuzzi G;
    Clin J Am Soc Nephrol; 2010 Nov; 5(11):1928-38. PubMed ID: 20671225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
    Muratti EN; Peters TK; Leitersdorf E
    Am J Cardiol; 1994 May; 73(14):30D-38D. PubMed ID: 8198022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Bortolini M; Salko T; Freudenreich MO; Isaacsohn JL; Troendle AJ; Gonasun L
    Am J Cardiol; 2003 Jan; 91(2):238-40. PubMed ID: 12521642
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of olmesartan in a patient with telmisartan-induced myotoxicity: a case report.
    Barvaliya MJ; Naik VN; Shah AC; Tripathi CR
    Br J Clin Pharmacol; 2015 Jun; 79(6):1034-6. PubMed ID: 25495498
    [No Abstract]   [Full Text] [Related]  

  • 13. Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats.
    Sugatani J; Sadamitsu S; Kurosawa M; Ikushiro S; Sakaki T; Ikari A; Miwa M
    Drug Metab Dispos; 2010 Oct; 38(10):1655-64. PubMed ID: 20587623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential warfarin-fluvastatin interaction.
    Kline SS; Harrell CC
    Ann Pharmacother; 1997 Jun; 31(6):790. PubMed ID: 9184730
    [No Abstract]   [Full Text] [Related]  

  • 15. Telmisartan induced urticarial vasculitis.
    Mahajan VK; Singh R; Gupta M; Raina R
    Indian J Pharmacol; 2015; 47(5):560-2. PubMed ID: 26600649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Critically appraised article].
    Neumann I; Grassi B
    Rev Med Chil; 2012 Jan; 140(1):117-20. PubMed ID: 22552566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
    Boncelj Svetek M; Eržen B; Kanc K; Šabovič M
    J Diabetes Complications; 2017 Mar; 31(3):544-550. PubMed ID: 28012835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of enhanced renin-angiotensin-aldosterone system inhibition with aliskiren in nondiabetic patients with chronic kidney disease.
    Lizakowski S; Tylicki L; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Pol Arch Med Wewn; 2013; 123(5):221-7. PubMed ID: 23615633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of fluvastatin with concomitant use of antihypertensive agents. An analysis of a clinical trial database.
    Peters TK; Jewitt-Harris J; Mehra M; Muratti EN
    Am J Hypertens; 1993 Nov; 6(11 Pt 2):346S-352S. PubMed ID: 7905274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.